Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Adverse Events | NCT00670982 | Neutropenia was the most prevalent adverse event in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00670982', 'Intervention': ['INTERVENTION 1: ', ' First Line Treatment', ' Patients with no prior therapy for metastatic breast cancer will receive bevacizumab intravenously every 2 weeks and vinorelbine intravenously once per week, and trastuzumab intravenously once per week', 'INTERVENTION... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f40c8d92-2921-45fd-8389-15048b08e229 | |
Comparison | Intervention | NCT00256698 | NCT03573804 | the primary trial and the secondary trial use completely different drugs and techniques for their interventions. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00256698', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant + Anastrozole', ' Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg', 'INTERVENTION 2: ', ' Anastrozole', 'Anastrozole 1 mg'], 'Eligibility': ['Inclusion Criteria:', ' Signed informed consent, postmenopausal females, hi... | {'Clinical Trial ID': 'NCT03573804', 'Intervention': ['INTERVENTION 1: ', ' Prone to Supine MRI Evaluated by Radiologist A', ' Radiologist A, number of participants successfully segmented', 'INTERVENTION 2: ', ' Prone to Supine MRI Evaluated by Radiologist B', ' Radiologist B, number of participants successfully se... | 31387af4-aad1-4f3c-bd81-641340ad4096 |
Single | Results | NCT00534417 | The median TTP in cohort one of the primary trial is just under 27 months. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00534417', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine and Fulvestrant', ' Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid i... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | eabe9a78-965e-4984-82c2-25598b6b35da | |
Single | Results | NCT01328249 | The Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01328249', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Eribulin Mesylate With Filgrastim as Needed', " Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles. Eribulin mesylate was admini... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 006f6b4e-6245-4f09-9786-327bbed3d766 | |
Single | Results | NCT00699491 | 3/4 participants in the primary trial suffered from Dose-limiting toxicities. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22
] | [] | {'Clinical Trial ID': 'NCT00699491', 'Intervention': ['INTERVENTION 1: ', ' Dose Level 1', ' 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22', ' 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 88b13330-b937-4bbc-80ea-4bf8ccc17bd1 | |
Comparison | Eligibility | NCT01009918 | NCT01688609 | There are no racial criteria for entry into the primary trial, but there are for the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20
] | [
17
] | {'Clinical Trial ID': 'NCT01009918', 'Intervention': ['INTERVENTION 1: ', ' Arm I Lisinopril', ' Patients receive oral lisinopril once daily.', ' lisinopril: Given orally', 'INTERVENTION 2: ', ' Arm II Coreg CR®', ' Patients receive oral Coreg CR® once daily.', ' Coreg CR®: Given orally'], 'Eligibility': ['INCLUS... | {'Clinical Trial ID': 'NCT01688609', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Lapatinib, Trastuzumab, Paclitaxel, Surgery)', ' Drug exposure: Patients receive lapatinib ditosylate PO QD and trastuzumab IV over 30-90 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicit... | e90e2368-808d-454d-8080-30427235b89d |
Single | Eligibility | NCT00723398 | Patients with both type 1 and 2 Diabetes are not suitable for the primary trial. | Entailment | [
5,
9
] | [] | {'Clinical Trial ID': 'NCT00723398', 'Intervention': ['INTERVENTION 1: ', ' Group 1: Control', ' Control, no intervention', 'INTERVENTION 2: ', ' Group 2: Raloxifene 60 mg', ' Raloxifene 60 mg Orally Daily'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal status defined as history of at least 12 months wi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d375ef3f-8b35-40eb-b9c0-3fc9592d9bec | |
Comparison | Intervention | NCT00245219 | NCT00038103 | the primary trial and the secondary trial only have test groups, so all patients are receiving novel (FDA approved) interventions. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00245219', 'Intervention': ['INTERVENTION 1: ', ' Health Tracking (Control)', ' Participants assigned to the health-tracking condition received usual care and did not attend any meetings.', 'INTERVENTION 2: ', ' Peer Support', ' The peer support group meetings focused on fostering purpose ... | {'Clinical Trial ID': 'NCT00038103', 'Intervention': ['INTERVENTION 1: ', ' Exemestane (Exemestane Alone)', ' oral dose exemestane taken with food (25 mg tablet once daily)', 'INTERVENTION 2: ', ' Combination (Exemestane + Celecoxib)', ' oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxi... | 2f2301cd-b8fa-47cc-94cc-e31150ce8f9e |
Comparison | Eligibility | NCT00248170 | NCT01299038 | Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is too old to participate in both the secondary trial and the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | {'Clinical Trial ID': 'NCT00248170', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' 2.5 mg by mouth (p.o.) once daily', 'INTERVENTION 2: ', ' Anastrozole', ' 1 mg p.o. once daily'], 'Eligibility': ['Inclusion Criteria:', ' Recent primary surgery for breast cancer', ' Early stage breast cancer', ' Postmenop... | {'Clinical Trial ID': 'NCT01299038', 'Intervention': ['INTERVENTION 1: ', ' Rosuvastatin 20mg', ' Rosuvastatin 20mg taken orally once a day for 4 weeks', ' rosuvastatin: Taken orally once a day for 4 weeks', 'INTERVENTION 2: ', ' Rosuvastatin 40mg', ' Rosuvastatin 40mg taken orally once a day for 4 weeks', ' rosu... | eea73ae4-0985-4f74-957d-e2aad7ab453c |
Single | Results | NCT00313170 | Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00313170', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 250 mg', 'Fulvestrant 250 mg', 'INTERVENTION 2: ', ' Fulvestrant 250 mg + Loading Dose', ' Fulvestrant 250 mg + Loading Dose'], 'Eligibility': ['Inclusion Criteria:', ' Breast Cancer has continued to grow after having received t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6550c068-14e6-4e93-8f98-756338c91e35 | |
Comparison | Intervention | NCT01293032 | NCT00849472 | None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or a support group course. | Entailment | [
0,
1,
2
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01293032', 'Intervention': ['INTERVENTION 1: ', ' Group 2 (RS 11-25)', ' Patients with an intermediate RS (11-25) were assigned to Group 2. The subject was then randomized to treatment Arm 1, neoadjuvant hormonal therapy, or treatment Arm 2, neoadjuvant chemotherapy.'], 'Eligibility': ['Incl... | {'Clinical Trial ID': 'NCT00849472', 'Intervention': ['INTERVENTION 1: ', ' AC, Followed by Weekly Paclitaxel and Concurrent Pazopanib', ' Participants were treated with intravenous (IV) doxorubicin (60 milligrams per meters squared [mg/m^2]) and cyclophosphamide (AC) (600 mg/m^2) every 21 days for 4 cycles. This was... | 0f5b81f0-b422-4000-8e0e-9f09c612ebc3 |
Comparison | Adverse Events | NCT00645333 | NCT00006110 | the primary trial records several immune system related adverse events in its patients, whereas the secondary trial does not. | Entailment | [
7,
8
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT00645333', 'Intervention': ['INTERVENTION 1: ', ' MK-0752 and Docetaxel', ' MK-0752 in escalating doses, orally days 1-3, followed by docetaxel 80 mg/m2 IV on day 8, and pegfilgrastim 6mg SQ day 9. Cycle repeated every 21 days.'], 'Eligibility': ['Inclusion Criteria:', ' Men or women with m... | {'Clinical Trial ID': 'NCT00006110', 'Intervention': ['INTERVENTION 1: ', ' Herceptin Regimen After AC', ' Patients in the adjuvant and neoadjuvant groups after receiving [AC-TP] Chemotherapy (doxorubicin & cyclophosphamide).', 'INTERVENTION 2: ', ' Herceptin Regimen After TP', ' Patients in the adjuvant and neoadj... | f6bba549-3d18-4a53-8685-96b4e321b1a7 |
Comparison | Intervention | NCT00602043 | NCT01720602 | Several treatments in the secondary trial and the primary trial are administered by mouth. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00602043', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic FES: Average FES SUVmean >1.5, no Negative Sites', ' Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.', ' P... | {'Clinical Trial ID': 'NCT01720602', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Vorinostat, AI Therapy)', ' Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat e... | 1fe36432-40f8-4c53-ac2b-0f8e50e5743f |
Comparison | Adverse Events | NCT01091454 | NCT00054275 | There were more cases of Anemia and vomiting in the primary trial than the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | {'Clinical Trial ID': 'NCT01091454', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Cisplatin and Brostallicin)', ' Patients receive 50 mg/m^2 cisplatin IV over 2 hours on day 1 and 10 mg/m^2 brostallicin IV over 10 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptabl... | {'Clinical Trial ID': 'NCT00054275', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel and OSI-774', ' docetaxel IV over 1 hour once weekly for 3 weeks and oral erlotinib once daily'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed stage IV or recurrent adenocarcinoma of the breast', ' Measur... | 3576f3e7-a1b9-4a75-934a-1ad2165b69dd |
Single | Adverse Events | NCT01446159 | the primary trial only had a total of 66 patients in across both its cohorts. | Contradiction | [
0,
1,
13,
14
] | [] | {'Clinical Trial ID': 'NCT01446159', 'Intervention': ['INTERVENTION 1: ', ' MEDI-573 10 mg/kg + Aromatase Inhibitor (AI)', " Participants enrolled in Phase 1b of the study and received intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | de71f285-4382-465f-9e7e-d163662f6d9c | |
Single | Adverse Events | NCT00281697 | the primary trial does not record any pain related adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT00281697', 'Intervention': ['INTERVENTION 1: ', ' Standard Chemotherapy + Bevacizumab', ' Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks dependin... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 406247fb-003a-47b7-8fe4-b6b963b98f08 | |
Comparison | Results | NCT02441946 | NCT00325598 | the secondary trial does not have a defined end date, whereas the primary trial lasted 2 weeks. | Contradiction | [
0,
3
] | [
0,
3
] | {'Clinical Trial ID': 'NCT02441946', 'Intervention': ['INTERVENTION 1: ', ' Abemaciclib + Anastrozole', ' Participants were given 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for 2 weeks.', ' All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for an... | {'Clinical Trial ID': 'NCT00325598', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1 (36 Gy)', ' 36 Gy in 9 fractions BID x 4 1/2 treatment days', ' Partial Breast Irradiation (PBI)', 'INTERVENTION 2: ', ' Cohort 2 (40 Gy)', ' 40 Gy in 10 fractions BID over 5 treatment days', ' Partial Breast Irradiation (PBI)'],... | 47553222-0aff-4394-bcfc-9f19c0863835 |
Single | Adverse Events | NCT00201864 | One patient in the primary trial had blood calcium levels far above normal. | Entailment | [
5
] | [] | {'Clinical Trial ID': 'NCT00201864', 'Intervention': ['INTERVENTION 1: ', ' Exemestane and Fulvestrant', ' Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection', ' Exemestane: 25 mg orally per day', ' Fulvestrant: 250 mg IM starting on Day 8 and then every 28 days.'], 'Eligibility': ['Inc... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e4756896-55c2-46e1-be19-14697ad3b39f | |
Comparison | Adverse Events | NCT02447003 | NCT00917735 | The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons. | Entailment | [
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26
] | [
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | {'Clinical Trial ID': 'NCT02447003', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Pembrolizumab', ' Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants were administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle ... | {'Clinical Trial ID': 'NCT00917735', 'Intervention': ['INTERVENTION 1: ', ' Green Tea Extract', ' Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8 ± 28.9 mg cat... | 594c9a79-d601-46b4-ae30-0b48a1117693 |
Comparison | Adverse Events | NCT02447003 | NCT00917735 | It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2 the primary trial, despite the difference in cohort size. | Contradiction | [
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26
] | [
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21
] | {'Clinical Trial ID': 'NCT02447003', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Pembrolizumab', ' Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants were administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle ... | {'Clinical Trial ID': 'NCT00917735', 'Intervention': ['INTERVENTION 1: ', ' Green Tea Extract', ' Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8 ± 28.9 mg cat... | 99e8ee0e-d72d-4e19-9424-20e5891bb2b6 |
Single | Adverse Events | NCT01273896 | There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial. | Entailment | [
0,
2,
8
] | [] | {'Clinical Trial ID': 'NCT01273896', 'Intervention': ['INTERVENTION 1: ', ' STA-9090', ' This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.', ' STA-9090: All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecut... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f1b0653f-b5ce-4558-b325-56244940c0cd | |
Single | Adverse Events | NCT01234402 | the primary trial at least 8 different types of cardiac related adverse events. | Contradiction | [
0,
4,
5,
6,
7,
8,
9,
10,
13,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT01234402', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab + Capecitabine', ' Participants received 10 milligram per kilogram (mg/kg) Ramucirumab intravenously on day 1 of 21 days cycle along with 1000 milligram per square meter (mg/m^2) of Capecitabine twice daily orally on days 1 to 14 ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 24b24d36-2500-4841-99a3-13cba905d77d | |
Single | Adverse Events | NCT00546104 | 1 patient in the primary trial suffered from a blood clot blocking their trachea. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00546104', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib', '50mg-100mg po BID'], 'Eligibility': ['Inclusion Criteria:', ' Measurable Stage IV or inoperable Stage III advanced breast cancer.', ' There is no limit on the number of prior therapies.', ' At least 3 weeks since prior chemothe... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0797ff90-f847-4442-92fd-017c539bb38f | |
Single | Intervention | NCT00606931 | the primary trial tests positron emission tomography as a technique for guiding a medical procedure. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00606931', 'Intervention': ['INTERVENTION 1: ', ' PET Guided Biopsy', ' No comparison group. All enrolled participants were expected to undergo PET guided biopsy.'], 'Eligibility': ['Inclusion Criteria:', ' Individuals aged 25 years or older', ' Individuals who have at least one breast ima... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6b595151-7e51-4062-b587-3207ea251677 | |
Comparison | Intervention | NCT04080297 | NCT02780713 | Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT04080297', 'Intervention': ['INTERVENTION 1: ', ' 100 mg Q-122', ' Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.', 'INTERVENTION 2: ', ' 200 mg Q-122', ' Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.']... | {'Clinical Trial ID': 'NCT02780713', 'Intervention': ['INTERVENTION 1: ', ' Treatment Period 1', ' Participants received AZD9496 - Variant A (100 mg).', 'INTERVENTION 2: ', ' Treatment Period 2', ' Participants received AZD9496 - Reference (100 mg).'], 'Eligibility': ['Inclusion Criteria:', ' Provision of signed a... | e802b1f6-62fb-4759-b261-c69dbdc1d7ef |
Comparison | Intervention | NCT00593346 | NCT00902330 | the primary trial treament last for a shorter period of time than the secondary trial treatment. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00593346', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Partial Breast Brachytherapy', ' Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.', ' Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given o... | {'Clinical Trial ID': 'NCT00902330', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Cranial Microcurrent Electrical Stimulation [CES])', ' Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is pr... | 0a24a07e-2cb4-4591-aea4-a370f462cc49 |
Comparison | Eligibility | NCT02322814 | NCT00356148 | A patient with Histologically confirmed estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor 2 positive breast cancer, with no known Brain metastases and no prior history of cardiac dysfunction, could be eligible for both the secondary trial and the primary trial. | Contradiction | [
0,
2,
22,
15,
33
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT02322814', 'Intervention': ['INTERVENTION 1: ', ' Cohort I: Cobimetinib, Paclitaxel', ' Participants received a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of ... | {'Clinical Trial ID': 'NCT00356148', 'Intervention': ['INTERVENTION 1: ', ' Prophylaxis Group', ' patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis', 'INTERVENTION 2: ', ' No Prophylaxis Group', ' Patients who are BMI over 25 and not receive antibiotic prophylaxis'], 'Eligibility': ['Inclu... | 97d0bbf0-c2c5-409b-820b-6e14a6326b06 |
Single | Eligibility | NCT00859651 | Helen had stage III ovarian cancer 7 years prior, but has been disease-free for 5 years., she is excluded from the primary trial. | Contradiction | [
13,
14
] | [] | {'Clinical Trial ID': 'NCT00859651', 'Intervention': ['INTERVENTION 1: ', ' Cholecalciferol 20,000 IU Group', ' Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.', 'INTERVENTION 2: ', ' Cholecalciferol 30,000 IU Gro... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | bbb5ebc0-83c8-46cb-89b4-e1c67e042350 | |
Single | Results | NCT00699491 | the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22
] | [] | {'Clinical Trial ID': 'NCT00699491', 'Intervention': ['INTERVENTION 1: ', ' Dose Level 1', ' 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22', ' 3 mg/ks cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 620106e8-2a7f-4078-80b6-d5f1840c66e1 | |
Single | Results | NCT00513292 | In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group had more Invasive Tumor Remaining in the Breast than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00513292', 'Intervention': ['INTERVENTION 1: ', ' FEC-75 Then Paclitaxel/Trastuzumab', ' Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 cour... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 94a7b007-0332-4d01-979e-9677e5da4316 | |
Single | Adverse Events | NCT00127205 | More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular systole. | Contradiction | [
10,
17,
18
] | [] | {'Clinical Trial ID': 'NCT00127205', 'Intervention': ['INTERVENTION 1: ', ' Arm I Zoledronate', ' Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.', ' zoledronic acid: Given IV', 'INTERVENTION 2: ', ' Arm II Clodronate', ' Patients receive oral c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2849d0ce-fed2-4c49-bec1-777c440caaeb | |
Single | Adverse Events | NCT00992225 | Only 2 of the 12 adverse event types recorded in the primary trial, occurred more than once. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00992225', 'Intervention': ['INTERVENTION 1: ', ' LY573636-sodium', ' Dose was adjusted to target a specific maximum concentration (Cmax) based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | aa6a20f8-ee49-42b7-9b9b-64caa8b22e35 | |
Comparison | Adverse Events | NCT01332630 | NCT00121134 | There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial, than in cohort 1 of the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT01332630', 'Intervention': ['INTERVENTION 1: ', ' TPI 287', ' TPI 287 administered at 160 mg/m2 by vein on Day 1 and repeated every three weeks. Day 1 of each subsequent cycle is equivalent of day 22 of the previous cycle; pre TPI 287: Dexamethasone 6 mg by mouth at 12 hours and 6 hours prio... | {'Clinical Trial ID': 'NCT00121134', 'Intervention': ['INTERVENTION 1: ', ' Group A- Bevacizumab Alone', ' Bevacizumab 15 mg/kg every 3 wks for 1 year', 'INTERVENTION 2: ', ' Group B-Bevacizumab+Cyclophosphamide+Methotrexate', ' Bevacizumab 15 mg/kg every 3 weeks for 1 year +Cyclophosphamide 50 mg orally daily for ... | 01a57096-0278-4c70-be43-acd57010cd6f |
Single | Intervention | NCT02953860 | Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study. | Entailment | [
3
] | [] | {'Clinical Trial ID': 'NCT02953860', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant With Enzalutamide', ' 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.', ' Fulvestrant w... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 49213077-0a5b-4368-a48a-282d2ca9d77a | |
Single | Results | NCT00263588 | All the primary trial subjects either had Progressive disease, Complete CNS objective response rate or partial response rate. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26
] | [] | {'Clinical Trial ID': 'NCT00263588', 'Intervention': ['INTERVENTION 1: ', ' Cohort A', ' 750mg lapatinib administered orally twice daily. Cohort A subjects had Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and one or two prior trastuzumab-containing regimens, in total, for treatment of breast canc... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 426d3ecd-73e3-4226-83c6-cfcb9212ed62 | |
Single | Results | NCT00696072 | 20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00696072', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib Plus Letrozole', ' Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years', ' Dasatinib 100 mg + Letrozole 2.5 mg', ' Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7c12676c-7973-4e9d-b1fc-3b14d241d0c8 | |
Comparison | Adverse Events | NCT01466972 | NCT01446159 | the primary trial recorded one patient with congestive Cardiac failure, the secondary trial recorded more. | Contradiction | [
0,
2
] | [
0,
5,
13,
18
] | {'Clinical Trial ID': 'NCT01466972', 'Intervention': ['INTERVENTION 1: ', ' Pazopanib in Combination With a NSAI', ' Non-randomized, open label', ' Pazopanib: Oral, 800mg tablet daily per cycle'], 'Eligibility': ['Inclusion Criteria:', ' Subjects must provide written informed consent prior to performance of study s... | {'Clinical Trial ID': 'NCT01446159', 'Intervention': ['INTERVENTION 1: ', ' MEDI-573 10 mg/kg + Aromatase Inhibitor (AI)', " Participants enrolled in Phase 1b of the study and received intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, ... | 3419e901-5880-488d-912c-023e8d1b51c7 |
Single | Intervention | NCT00748553 | Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle | Contradiction | [
0,
1,
2,
3
] | [] | {'Clinical Trial ID': 'NCT00748553', 'Intervention': ['INTERVENTION 1: ', ' Phase 1', ' Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle', ' Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle'], 'Eligibility': ['Inclusion Criteria:', ' For phase I, a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | cd645637-0a31-4f54-bc75-4a52349cf100 | |
Single | Adverse Events | NCT02115984 | A total of 3 patients in the primary trial experience a Herpes related adverse event. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT02115984', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy & Panagen', ' Chemotherapy: Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.', ' Panagen 5 mg tablet by mouth every 2-3 h (six times a ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | adfc79ba-2996-47ce-9986-7d287931df89 | |
Comparison | Results | NCT01129336 | NCT01945775 | 16 participants of the primary trial are considered to be censored. the secondary trial used the same outcome measurement, but had no censored patients. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT01129336', 'Intervention': ['INTERVENTION 1: ', ' Patients Without Bone Metastases', ' Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.', 'INTERVENTION 2: ', ' Patient... | {'Clinical Trial ID': 'NCT01945775', 'Intervention': ['INTERVENTION 1: ', ' Talazoparib', " Participants received talazoparib 1 mg, orally, once daily until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or spo... | 414ae027-b420-4f01-afd5-164cd8146a30 |
Single | Intervention | NCT00470847 | the primary trial participants will not receive any Lapatinib post WBRT. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00470847', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib,Whole Brain Radiation,Herceptin', ' Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically-confirmed invasive br... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 45b2b9ec-ba58-4323-810a-4baed9c84a0e | |
Single | Eligibility | NCT00971945 | Patients must have already participated in a specific clinical study to participate in the primary trial. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00971945', 'Intervention': ['INTERVENTION 1: ', ' Treatment Arm', ' Paclitaxel 100 mg/m2 IV administered on Days 1, 8, 15, 22, 29, 36 and then suspended until Day 49 (1 course comprised of 49 days).'], 'Eligibility': ['Inclusion Criteria:', ' Subjects who were confirmed to have a response a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 72ffdfbf-aa72-4d44-814a-1d6ab8883898 | |
Single | Adverse Events | NCT00403130 | There were no cases of Leukopenia or Arrhythmia observed in patients participating in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00403130', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab + Gemcitabine + Paclitaxel', ' Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles', ' Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles', ' Bevacizumab 10 mg/kg by IV infusion, days 1 ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | db613a72-e300-41a7-987f-788c306d94a4 | |
Single | Intervention | NCT02202252 | The difference between cohort 1 and 2 of the primary trial is the insertion of an additional negative pressure drain for patients in cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
5,
10,
5
] | [] | {'Clinical Trial ID': 'NCT02202252', 'Intervention': ['INTERVENTION 1: ', ' Single Drain', ' Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.', ' Ultrasonography after removal of the drains: One day after removal of the dr... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2667d301-2efb-4d92-bc12-ccfc869e4835 | |
Single | Adverse Events | NCT00934856 | In total, across both cohorts of the primary trial, there was at least 2 fatigued patients. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00934856', 'Intervention': ['INTERVENTION 1: ', ' MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (Over 2 Days)', ' Participants with HER2-positive MBC received docetaxel 75 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 60bff573-0251-4f05-b2b7-dec74c7363cc | |
Comparison | Eligibility | NCT01581619 | NCT01008150 | histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial, but not from the secondary trial. | Entailment | [
4,
10
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38,
39,
40,
41,
42,
43
] | {'Clinical Trial ID': 'NCT01581619', 'Intervention': ['INTERVENTION 1: ', ' Partial Breast Irradiation', ' Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks', ' External Beam Partial-Breast Irradiation: 40 Gy in ten daily fractions over two weeks'], 'Eligibility': ['Inclusion Criteria:', ' Unicent... | {'Clinical Trial ID': 'NCT01008150', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Paclitaxel + Trastuzumab Then A C', ' 4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Followin... | f6f8a0d3-6288-44cf-9b34-27444110dd10 |
Comparison | Intervention | NCT00572728 | NCT02472964 | Patients in the primary trial and the secondary trial will take Herceptin© (trastuzumab) or paclitaxel intravenously. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT00572728', 'Intervention': ['INTERVENTION 1: ', ' Diagnostic (18F-FLT)', ' Patients undergo 18F-FLT PET/CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery,... | {'Clinical Trial ID': 'NCT02472964', 'Intervention': ['INTERVENTION 1: ', ' Herceptin© + Taxane', ' Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint... | 8b0482c1-74d4-48ae-96bc-d80f8f1a0f50 |
Single | Eligibility | NCT00836186 | Patients cannot be excluded from the primary trial on the basis of race or ethnicity. | Entailment | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00836186', 'Intervention': ['INTERVENTION 1: ', ' Radiation Therapy', ' Women with any non-metastatic breast cancer status post lumpectomy to negative margins and who are receiving whole breast irradiation as per standard treatment plan.', ' Radiation therapy: Patients will receive whole br... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 878dcfeb-c3db-4077-9a3e-8098efa80a99 | |
Comparison | Eligibility | NCT04396665 | NCT00493636 | Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet. | Contradiction | [
0,
1,
2,
3,
4
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36,
37,
38
] | {'Clinical Trial ID': 'NCT04396665', 'Intervention': ['INTERVENTION 1: ', ' Intervention Group', ' Women in the intervention group', 'INTERVENTION 2: ', ' Control Group', ' Women in the control group'], 'Eligibility': ['Inclusion Criteria:', ' Informed consent signed', ' Capability to use internet', 'Exclusion Cr... | {'Clinical Trial ID': 'NCT00493636', 'Intervention': ['INTERVENTION 1: ', ' A (Sorafenib + Gemcitabine or Capecitabine)', ' Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Cape... | fc5dbfec-ba79-4c5d-9e38-3c97d0397570 |
Comparison | Adverse Events | NCT01234337 | NCT00217672 | No cases of Anaphylaxis occurred in either the primary trial or the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT01234337', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib (Nexavar, BAY43-9006) + Capecitabine', ' Sorafenib tablets were administered orally continuously at a total daily dose of 600 mg (200 mg in the morning, 400 mg in the evening) in a 3-week cycle. Capecitabine was administered orally ... | {'Clinical Trial ID': 'NCT00217672', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel + Bevacizumab', ' docetaxel: 75 mg/m2 IV q3 weeks. Bevacizumab: 15mg/kg IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.'], 'Eligibility': [... | a8514489-cb31-4c8a-abca-e1f7b3a8d4ce |
Comparison | Intervention | NCT03210220 | NCT00290745 | Unlike the primary trial, the secondary trial has no control group. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6
] | {'Clinical Trial ID': 'NCT03210220', 'Intervention': ['INTERVENTION 1: ', ' Pecs Group', ' Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral bran... | {'Clinical Trial ID': 'NCT00290745', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen or Letrozole', ' tamoxifen or letrozole work in treating women with ductal carcinoma in situ', ' letrozole', ' tamoxifen citrate', ' conventional surgery', ' neoadjuvant therapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' ... | 64411610-090b-42d2-a176-d2b13ffef591 |
Comparison | Intervention | NCT02364388 | NCT01425268 | warm saline solution is used in both the primary trial and the secondary trial. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT02364388', 'Intervention': ['INTERVENTION 1: ', ' MAESTRO', 'Baseline'], 'Eligibility': ['Inclusion Criteria', ' Female', ' 18 years of age or older', ' Have an undiagnosed suspicious finding which may include more than one solid or complex cystic suspicious mass, classified by CDU as BI-R... | {'Clinical Trial ID': 'NCT01425268', 'Intervention': ['INTERVENTION 1: ', ' AeroForm Tissue Expansion', ' AeroForm Tissue Expansion inflation with carbon dioxide by remote control', ' AeroForm Tissue Expansion: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy... | 82bd50ac-9407-413b-9eb8-653cef49706c |
Comparison | Intervention | NCT02122796 | NCT01575522 | The intervention section for the primary trial does not detail the type or duration of the intervention, unlike the secondary trial. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4
] | {'Clinical Trial ID': 'NCT02122796', 'Intervention': ['INTERVENTION 1: ', ' Patients Undergoing Mastectomy Surgery', ' Number of individuals having mastectomy surgery who were approached for participation in the trial'], 'Eligibility': ['Inclusion Criteria:', ' Women', ' 18 years or older', ' Undergoing mastectomy... | {'Clinical Trial ID': 'NCT01575522', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Tivantinib)', ' Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically dur... | 470611af-16b2-4094-ae2a-c9c6155e2672 |
Single | Adverse Events | NCT00693719 | the primary trial recorded less than 3 different Adverse Events . | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00693719', 'Intervention': ['INTERVENTION 1: ', ' Etoposide/Irinotecan', ' Irinotecan hydrochloride : Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle', ' Etoposide : 50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of lo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f3a03aec-194d-4538-9be3-cea8281d995c | |
Comparison | Intervention | NCT00911898 | NCT02352779 | the primary trial and the secondary trial do not explain their interventions in the intervention section. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT00911898', 'Intervention': ['INTERVENTION 1: ', ' MM-111', 'All participants'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically or cytologically confirmed advanced cancer that is:', ' HER2 amplified (IHC 2+ or greater) based on archived tumor evaluation', ' Hereg... | {'Clinical Trial ID': 'NCT02352779', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Low-dose Omega-3 Fatty Acid)', ' Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.', 'Omega-3 Fatty Acid: Given PO', ' Placebo: Given PO', ' Questionnaire Administration: Ancillary st... | 14a5e557-b223-4649-9867-0ff0e9001f5e |
Single | Intervention | NCT03329937 | the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 3 cycles, after which all participants undergo neoadjuvant chemotherapy. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT03329937', 'Intervention': ['INTERVENTION 1: ', ' Niraparib 200 mg', " Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles. After 2 cycles, participants either underwent surgery, received additional cycles of niraparib (maximum of 6 cycles total),... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c8df3461-4063-4fb0-ae48-f57062eb0a68 | |
Comparison | Intervention | NCT01539317 | NCT01323530 | the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01539317', 'Intervention': ['INTERVENTION 1: ', ' Topical Saline', ' Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule', ' Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness', 'INTERVENTION 2:... | {'Clinical Trial ID': 'NCT01323530', 'Intervention': ['INTERVENTION 1: ', ' Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2)', ' Participants received eribulin mesilate 1.2 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day ... | 1cd7cf90-bf66-480b-9227-2f7d2eccd647 |
Single | Results | NCT00370552 | There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00370552', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg', ' Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, adm... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 15f9d033-ebf7-44b3-94e2-3b8ee90b862b | |
Single | Adverse Events | NCT00266799 | None of the patients in cohort 1 of the primary trial had Acute coronary syndrome. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14
] | [] | {'Clinical Trial ID': 'NCT00266799', 'Intervention': ['INTERVENTION 1: ', ' Pegylated Liposomal Doxorubicin (PLD)', ' PLD 50 mg/m^2 was administered intravenously once every 28 days. Each cycle was repeated until progress or unacceptable toxicity.', 'INTERVENTION 2: ', ' Capecitabine', ' Capecitabine 1250 mg/m^2, i... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d | |
Single | Eligibility | NCT02995980 | A patient presenting Glomerular filtration rate of 63, a severe iodinated contrast allergy and with BI-RADS category c breast tissue would be eligilbe for the primary trial. | Contradiction | [
0,
3,
4,
5,
6
] | [] | {'Clinical Trial ID': 'NCT02995980', 'Intervention': ['INTERVENTION 1: ', ' Contrast Enhanced Mammography', ' Contrast-enhanced spectral mammography for the detection breast cancer .', ' DECE mammography: Contrast mammography', 'INTERVENTION 2: ', ' Standard Digital Mammogram', ' Full field digital mammography for... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 51cf1333-78b1-410a-82fe-aabfaa00a840 | |
Single | Results | NCT00662025 | on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00662025', 'Intervention': ['INTERVENTION 1: ', ' SUNITINIB+CAPECITABINE', ' Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles. Capecitabine was administered orally from Days 1 to 14 every 21 days at a star... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d | |
Comparison | Adverse Events | NCT00570921 | NCT00274456 | There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial, but none in cohort 1 of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
13,
14,
15,
3,
4,
5,
19,
20,
21,
22,
10,
11,
25
] | {'Clinical Trial ID': 'NCT00570921', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant + Everolimus', ' Fulvestrant + Everolimus', ' Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day ... | {'Clinical Trial ID': 'NCT00274456', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 300 mg/m^2 q3w', ' ABI-007 300 mg/m^2 administered once every third week (q3w).', 'INTERVENTION 2: ', ' ABI-007 100 mg/m^2 Weekly', ' ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest'], 'Eligibility': ['Inclusio... | aef2367d-78a5-4dc7-a6f7-d96415082362 |
Single | Adverse Events | NCT00201851 | There were no cases of Oesophageal spasming, Diastolic dysfunction or thrombosis observed in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00201851', 'Intervention': ['INTERVENTION 1: ', ' A - Scheduled Surgery', ' Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen', ' Tamoxifen: 20 mg po daily x 5 years', ' Surgery: Oophorectomy: Group A-Surgical oophorectomy and mastectomy in estimated 5 ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 29ae75a2-d8d2-4427-bba3-ab2c411d5718 | |
Single | Adverse Events | NCT00475670 | compared to cohort 1 of the primary trial, other than sudden death, there are more cases of every observed adverse event in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00475670', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Monotherapy', ' Participants received either an initial loading dose of trastuzumab 4 mg/kg, IV, on Day 1, followed by 2 mg/kg, IV, once per week, or an initial loading dose of 8 mg/kg IV on Day 1, followed by 6 mg/kg IV once ever... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 985c4cb3-2684-4a67-a479-998602044a0d | |
Comparison | Adverse Events | NCT00107276 | NCT00232505 | Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial experienced an adverse event, and less than a 1/3 of those in cohort 2 of the secondary trial had adverse events. | Contradiction | [
0,
1
] | [
0,
1,
8,
9
] | {'Clinical Trial ID': 'NCT00107276', 'Intervention': ['INTERVENTION 1: ', ' Cyclophosphamide and Capecitabine', ' cyclophosphamide orally days 1-14 and capecitabine orally days 15-21 for 8 cycles of 21 days each'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically or cytologically confirmed stage IV breas... | {'Clinical Trial ID': 'NCT00232505', 'Intervention': ['INTERVENTION 1: ', ' Cetuximab', ' Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II.', ' c... | 39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3 |
Single | Eligibility | NCT00617539 | Patients with Extracranial metastases are still permited to enter in the primary trial. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00617539', 'Intervention': ['INTERVENTION 1: ', ' Irinotecan and Temozolomide', ' irinotecan hydrochloride administered intravenously (IV) at a starting dose of 125 mg/m2 on days 1 and 15 of a 28 day cycle', ' temozolomide orally for seven days at a starting dose of 100 mg/m2 on days 1-7 an... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d695120e-db68-481d-9023-881e48654e29 | |
Single | Intervention | NCT00941330 | Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00941330', 'Intervention': ['INTERVENTION 1: ', ' A: Exemestane', ' ARM A: Patients will be treated with exemestane.', ' Exemestane: 25 mg daily by mouth for 6 to 12 months.', 'INTERVENTION 2: ', ' B: Docetaxel and Cytoxan', ' ARM B: Patients will be treated with docetaxel and cytoxan.', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5319ac1a-07ae-4531-bf93-5fce83016c87 | |
Single | Eligibility | NCT00388726 | A 75 year old female patient, with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial. | Contradiction | [
0,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00388726', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/kg^2', ' Eribulin Mesylate 1.4 mg/kg^2 on Days 1 and 8', 'INTERVENTION 2: ', " Treatment of Physician's Choice", " Treatment of Physician's Choice"], 'Eligibility': ['Inclusion Criteria:', ' Female patients with hi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 087aba29-40c6-4453-a44b-e63c3867e5b4 | |
Comparison | Eligibility | NCT03624972 | NCT01216176 | A 72 year old patient suffering from dementia would be excluded from both the secondary trial and the primary trial. | Entailment | [
4,
7
] | [
56,
73
] | {'Clinical Trial ID': 'NCT03624972', 'Intervention': ['INTERVENTION 1: ', ' Resources Only', ' Patients will receive a list of resources on sexual and menopausal health in breast cancer. They will be asked to review the resources before their next clinic visit.', ' Sexual and Menopausal Health Resources: Patients wi... | {'Clinical Trial ID': 'NCT01216176', 'Intervention': ['INTERVENTION 1: ', ' Phase 1 - Cohort A', ' Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer', ' Anastrozole',... | c66f3e9e-f232-4035-b705-2785946d1542 |
Comparison | Intervention | NCT01390064 | NCT00485953 | All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01390064', 'Intervention': ['INTERVENTION 1: ', ' Initial Cohort', ' Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms', ' Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimoto... | {'Clinical Trial ID': 'NCT00485953', 'Intervention': ['INTERVENTION 1: ', ' Active Medicine Group', ' risedronate 35 mg weekly', 'INTERVENTION 2: ', ' Placebo Group', ' Received placebo medication once weekly'], 'Eligibility': ['Inclusion Criteria:', ' elderly postmenopausal women (ages 55 and older)', ' osteopen... | c679f426-b235-4ae9-ad6c-4f1a46a494d2 |
Single | Adverse Events | NCT00879086 | Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 8 more cases of Leukopenia than cohort 2. | Contradiction | [
0,
3,
4,
5,
14,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00879086', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate was given at a dose of 1.4 mg/m^2 as a 2 to 5 minute IV bolus on Days 1 and 8 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cy... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 122b1aef-4506-464d-9852-47caa508b047 | |
Comparison | Results | NCT00841828 | NCT01959490 | All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | {'Clinical Trial ID': 'NCT00841828', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: EC -> D + Lapatinib', ' EC -> D + Lapatinib', ' Drugs plus Biological', ' Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -> Docetaxel (D) + lapatinib each 21 days for 4 cycles)', 'INTERVENTION 2: ', ' Arm 2: EC -> D + ... | {'Clinical Trial ID': 'NCT01959490', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1P (HER2 Positive)', ' Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1... | 4a4f3e9e-6a29-4715-8000-2eec90e9bb5d |
Comparison | Eligibility | NCT00297596 | NCT00580333 | Patients who completed a trastuzumab regiment, to treat the current breast cancer > 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial. | Entailment | [
0,
8,
10
] | [
8,
9
] | {'Clinical Trial ID': 'NCT00297596', 'Intervention': ['INTERVENTION 1: ', ' Oxaliplatin/Trastuzumab', ' Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days. Oxalipla... | {'Clinical Trial ID': 'NCT00580333', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin/Avastin', ' Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)', ' cisplatin: Preopera... | 9f7dc38b-1945-4035-a0ff-e08ead55145b |
Single | Eligibility | NCT01525589 | People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial. | Contradiction | [
0,
13
] | [] | {'Clinical Trial ID': 'NCT01525589', 'Intervention': ['INTERVENTION 1: ', ' Cohort A (BRCA+)', ' Patients with known deleterious BRCA1/2 mutation status at study entry', 'INTERVENTION 2: ', ' Cohort A1 (BRCA+/PARPi)', ' Patients with known deleterious BRCA1/2 mutation status and prior treatment with PARPi.'], 'Elig... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b259774e-410a-49aa-b5d4-31b8d9505fc3 | |
Comparison | Adverse Events | NCT01565499 | NCT01234402 | Some of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different breathing related issues. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | {'Clinical Trial ID': 'NCT01565499', 'Intervention': ['INTERVENTION 1: ', ' Nab-Paclitaxel', ' The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.', 'Nab-paclitaxel'], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically conf... | {'Clinical Trial ID': 'NCT01234402', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab + Capecitabine', ' Participants received 10 milligram per kilogram (mg/kg) Ramucirumab intravenously on day 1 of 21 days cycle along with 1000 milligram per square meter (mg/m^2) of Capecitabine twice daily orally on days 1 to 14 ... | e09a11e4-afc8-4351-a5bc-d847424c79ce |
Comparison | Intervention | NCT01720602 | NCT00082810 | the primary trial participants receive more anastrozole, Fulvestrant and exemestane than patients in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01720602', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Vorinostat, AI Therapy)', ' Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat e... | {'Clinical Trial ID': 'NCT00082810', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 250 mg + Tipifarnib 300 mg', ' Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable to... | d22f01f0-b2be-45b9-8996-11727750b91e |
Single | Adverse Events | NCT00129935 | There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00129935', 'Intervention': ['INTERVENTION 1: ', ' Arm A: EC-T', ' Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycle... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 893d5684-03f8-4acd-86e4-6d38eea3ce16 | |
Comparison | Adverse Events | NCT01596751 | NCT00193050 | There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts. | Entailment | [
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT01596751', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib: Eribulin in Combination With PLX3397', ' Phase Ib:', ' 21 day treatment cycle: PLX3397 100-200 mg gelcaps, by mouth daily & Eribulin 1.4 mg/m2 intravenously, day 1 and 8', ' Cohort 1: 600 mg/day', ' Cohort 2: 800 mg/day', ' Coho... | {'Clinical Trial ID': 'NCT00193050', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles', ' Patients then ha... | 4b46164d-a4c2-4738-be36-588ab231ceb1 |
Single | Adverse Events | NCT00320541 | Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1. | Contradiction | [
0,
4,
13,
17
] | [] | {'Clinical Trial ID': 'NCT00320541', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel Plus Bevacizumab (PB)', ' paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d9236874-7f3d-4402-9699-2889db9f5c61 | |
Comparison | Results | NCT00057941 | NCT01806259 | DLT occurence, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT00057941', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole and ZD1839', '[Not Specified]', 'INTERVENTION 2: ', ' Fulvestrant and ZD1839', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have estrogen and/or progesterone receptor positive histologically confirme... | {'Clinical Trial ID': 'NCT01806259', 'Intervention': ['INTERVENTION 1: ', ' Ketorolac 30 mg', ' Active drug to be compared with placebo', 'Ketorolac 30 mg IV', 'INTERVENTION 2: ', ' NaCl 0.9% 3mL', 'Ketorolac 30 mg IV'], 'Eligibility': ['Inclusion Criteria:', ' Written informed Consent age : 18-85 years weight: 50-... | e33825f1-45df-41f5-ba07-e9059636a146 |
Comparison | Results | NCT00295620 | NCT03366428 | the secondary trial and the primary trial use similar outcome measures, evaluating how long patients survive after treatment. | Contradiction | [
0,
1,
2
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00295620', 'Intervention': ['INTERVENTION 1: ', ' Arm A: Anastrozol', ' 1 mg per day for 2 years', 'INTERVENTION 2: ', ' Arm B: Anastrozol', ' 1 mg per day for 5 years'], 'Eligibility': ['Inclusion criteria:', ' Postmenopausal patients with histologically confirmed, local radically treate... | {'Clinical Trial ID': 'NCT03366428', 'Intervention': ['INTERVENTION 1: ', ' DS-8201a', ' Participants who received 6.4 mg/kg of DS-8201a as an intravenous (IV) infusion once every 3 weeks on Day 1 of each 21-day cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Has a pathologically documented unresectable or metast... | 5b0295e1-a322-40af-9acf-9cc1d55d3e64 |
Single | Eligibility | NCT00077857 | Patients must be older than 18, female, have three or more target lesions and more than 1 regiment of chemotherapy to participate in the primary trial. | Contradiction | [
0,
1,
2,
5
] | [] | {'Clinical Trial ID': 'NCT00077857', 'Intervention': ['INTERVENTION 1: ', ' 1250 mg/m^2 Capecitabine + Docetaxel', ' 1250 mg/m^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.', 'INTERVENTIO... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3658f2f7-a497-4abb-badb-c877036456f2 | |
Single | Results | NCT00303108 | The Cohort of the primary trial which received D+C and Taxane Na‚àö√òve, produced marginally better results than the other cohort. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00303108', 'Intervention': ['INTERVENTION 1: ', ' D+C and Taxane Naive', ' Doxil, Carboplatin and Taxane naive', 'INTERVENTION 2: ', ' D+C and Taxane Pretreated', ' Doxil, Carboplatin and Taxane pretreated'], 'Eligibility': ['Inclusion Criteria:', ' Has metastatic breast cancer with docum... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 37bc71d5-d9c0-4174-8da5-725d2d53a91b | |
Comparison | Intervention | NCT02781051 | NCT01067976 | The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, no physical activity is explicitly required for the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT02781051', 'Intervention': ['INTERVENTION 1: ', ' Physical Activity Intervention', ' Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.', ' Print-based education: Subjects were given a copy of Exercise for Health: An Exer... | {'Clinical Trial ID': 'NCT01067976', 'Intervention': ['INTERVENTION 1: ', ' CMRM vs UMRM', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology [ACR... | 51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c |
Single | Results | NCT01302379 | Both patient cohorts of the primary trial had a median Insulin change from baseline lower than -15%. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT01302379', 'Intervention': ['INTERVENTION 1: ', ' Metformin + Lifestyle Intervention', ' Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time', ' Lifestyle intervention: Telephone-based lifestyle intervention (dietary... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8bcc9fa3-0317-471a-a5b5-b115b5b72dea | |
Single | Results | NCT00082433 | the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, triples patient OS, compared to Capecitabine alone. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00082433', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone + Capecitabine', ' Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a da... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 52610141-321d-4e3d-8660-ebc14b9f1696 | |
Comparison | Adverse Events | NCT00570921 | NCT00274456 | There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial, but none in cohort 1 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT00570921', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant + Everolimus', ' Fulvestrant + Everolimus', ' Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day ... | {'Clinical Trial ID': 'NCT00274456', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 300 mg/m^2 q3w', ' ABI-007 300 mg/m^2 administered once every third week (q3w).', 'INTERVENTION 2: ', ' ABI-007 100 mg/m^2 Weekly', ' ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest'], 'Eligibility': ['Inclusio... | 90203158-6477-4486-b8d9-09dcaca63617 |
Comparison | Adverse Events | NCT00574587 | NCT00777049 | There were no cases of Myocardial ischaemia in the primary trial or the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT00574587', 'Intervention': ['INTERVENTION 1: ', ' Stratum A: VR-Paclitaxel-Trastuzumab', ' Stratum A: Vorinostat 200 (Dose Level 1) or 300 mg (Dose level 2) by mouth on days 1-3 plus weekly paclitaxel 80 mg x 12 weeks and trastuzumab 4 mg/kg, then 2 mg/kg x 12 weeks, followed by doxorubicin ... | {'Clinical Trial ID': 'NCT00777049', 'Intervention': ['INTERVENTION 1: ', ' ER+ and/or PgR+ (Arm I)', ' Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg', 'INTERVENTION 2: ', ' ER- and PgR- (Arm II)', ' Panobinostat - LBH589: hard gelatine capsule - 5mg and 20mg'], 'Eligibility': ['Inclusion Criteria:', ... | 03334f23-49ab-47e5-b420-a6753ce6e832 |
Single | Adverse Events | NCT02370238 | There were 2 cases of Angina in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT02370238', 'Intervention': ['INTERVENTION 1: ', ' Paclitaxel+Reparixin (Group 1) - ITT Population', ' paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle.', ' Duration of Treatment: 28-day cycles of combination t... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a847cfc1-9556-4a55-9698-69c22696148f | |
Single | Adverse Events | NCT01075100 | No mental health issues were observed in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29
] | [] | {'Clinical Trial ID': 'NCT01075100', 'Intervention': ['INTERVENTION 1: ', ' Triple Negative', ' ER-/PR-/HER2- patients who received Ixabepilone 20 mg/m2 on Days 1 and 8 and Carboplatin AUC=2.5 on Days 1 and 8 of each 21-day cycle.', 'INTERVENTION 2: ', ' HR Positive', ' ER+/PR+/HER2-, or ER+/PR-/HER2-, or ER-/PR+/H... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | fcbb7e0f-d106-44bd-a252-9b57adc6f071 | |
Single | Results | NCT03584009 | Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 160 mg of Neratinib. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT03584009', 'Intervention': ['INTERVENTION 1: ', ' Venetoclax + Fulvestrant', ' Participants were administered Venetoclax 800mg orally QD and Fulvestrant 500mg IM on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).', 'INTERVENTION 2: ', ' Fulvestrant', ' Part... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | f82d94fe-c633-4bae-b28d-074196a08577 | |
Comparison | Intervention | NCT00659373 | NCT02202252 | the primary trial has a 5 year long intervention, the duration of the secondary trial is not specified in the intervention section. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
5,
10,
5
] | {'Clinical Trial ID': 'NCT00659373', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen', ' Tamoxifen 20mg orally daily for 5 years', 'INTERVENTION 2: ', ' Ovarian Function Suppression', ' Tamoxifen 20mg orally daily or Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH... | {'Clinical Trial ID': 'NCT02202252', 'Intervention': ['INTERVENTION 1: ', ' Single Drain', ' Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.', ' Ultrasonography after removal of the drains: One day after removal of the dr... | e5379a89-f880-44c1-bee0-a0d8ad2abfce |
Single | Eligibility | NCT00717886 | Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial, patients with prior High-dose chemotherapy can still enter if they satisfy all other inclusion criteria. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00717886', 'Intervention': ['INTERVENTION 1: ', ' Upper Extremity Lymphatic Mapping for Breast Cancer Patients', ' Patients with documented axillary metastases (Stage II breast cancer) will undergo subdermal injection of technetium sulfur colloid (TSC) into the ipsilateral upper extremity ap... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d811aaec-b3bd-4376-a9d6-d14eacae875a | |
Single | Eligibility | NCT00050167 | Only Patients with metastasis in less than 9 infraclavicular lymph nodes are eligible for the primary trial. | Contradiction | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT00050167', 'Intervention': ['INTERVENTION 1: ', ' Weekly Paclitaxel (WP)', ' Weekly Paclitaxel for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles', 'INTERVENTION 2: ', ' Docetaxel and Capecitabine (DX)', ' Docetaxel + Capecitabine days 1-... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 99312d82-614c-4422-b6e6-104fe5a7fa54 | |
Comparison | Adverse Events | NCT02049957 | NCT01506609 | There is are the same total number of patients in the primary trial as in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT02049957', 'Intervention': ['INTERVENTION 1: ', ' Phase 1 (Part 1): Sapanisertib 5 mg + Exemestane', ' Sapanisertib 5 mg, unmilled active pharmaceutical ingredient (API) capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 12 cycles).', 'I... | {'Clinical Trial ID': 'NCT01506609', 'Intervention': ['INTERVENTION 1: ', ' Group 2 Placebo + Carboplatin/Paclitaxel', ' Placebo BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.', 'INTERVENTION 2: ', ' ... | b02c99f3-70bd-4404-8d80-c57c6dfef7b7 |
Single | Adverse Events | NCT00454532 | Less than half of patients in cohorts 1 in the primary trial experienced adverse events, but more than 45% of patients cohort 2 did experience adverse events. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT00454532', 'Intervention': ['INTERVENTION 1: ', ' Level 1', '10g/day', 'INTERVENTION 2: ', ' Level 2', '20g/day'], 'Eligibility': ['Key Inclusion Criteria:', ' Women 18 years or older', ' Histologically confirmed breast cancer', ' Clinical evidence of metastatic (stage IV) metastasis (oth... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3cbf2726-ddb0-460c-9dd2-082b8dda495d | |
Comparison | Intervention | NCT01912612 | NCT02392611 | In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the intervention, but cohort 2 recieves more than double the dose of cohort 1. | Entailment | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT01912612', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Patients With Pain)', ' Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.', ' Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then ... | {'Clinical Trial ID': 'NCT02392611', 'Intervention': ['INTERVENTION 1: ', ' Monotherapy: Alobresib 0.6 mg', ' Participants with advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy, or for whom no standard therapy existed received alobresib tablets at a dose of 0.6 mg orally once ... | e7741151-2b2c-4e78-a4df-fe998c580714 |
Single | Results | NCT00376688 | Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00376688', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Temsirolimus)', ' Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.', ' Temsirolimus: Given IV'], 'Eligibility':... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8cff36b0-a022-4469-8d14-7120be891cb1 | |
Comparison | Eligibility | NCT00304096 | NCT00876395 | A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial. | Contradiction | [
14
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20
] | {'Clinical Trial ID': 'NCT00304096', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1: Received Hormonal Therapy', ' Participants received hormonal therapy', 'INTERVENTION 2: ', ' Stratum 2: Had Not Received Hormonal Therapy', ' Participants had not received hormonal therapy'], 'Eligibility': ['DISEASE CHARACTERIST... | {'Clinical Trial ID': 'NCT00876395', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Paclitaxel + Trastuzumab', ' Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22', 'INTERVENTION 2: ', ' Placebo + Paclitaxel + Trastuzumab', '... | 4ce24508-3d12-499f-ab7f-4b437ea51366 |
Single | Results | NCT00633464 | The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT00633464', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 40 mg/m^2', ' ixabepilone 40 mg/m^2 every 3 weeks', 'INTERVENTION 2: ', ' Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2', ' cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks'], 'Eligib... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2514da19-b30a-44bb-8853-4545e97295da |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.